Patterns of Molecular Response to and Relapse After Combination of Sorafenib, Idarubicin, and Cytarabine in Patients with Newly Diagnosed FLT3-Mutant Acute Myeloid Leukemia (AML)

被引：0
|
作者：
Al-Kali, Aref [1 ]
Jones, Dan [1 ]
Cortes, Jorge [1 ]
Faderl, Stefan [1 ]
Ao, Xue [1 ]
Garcia-Manero, Guillermo [1 ]
Borthakur, Gautam [1 ]
Konopleva, Marina [1 ]
Brandt, Mark [1 ]
Andreeff, Michael [1 ]
Kantarjian, Hagop [1 ]
Ravandi, Farhad [1 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
BLOOD | 2009年 / 114卷 / 22期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：820 / 821
页数：2
相关论文
共 50 条
  • [1] Patterns of Molecular Response to and Relapse After Combination of Sorafenib, Idarubicin, and Cytarabine in Patients With FLT3 Mutant Acute Myeloid Leukemia
    Al-Kali, Aref
    Cortes, Jorge
    Faderl, Stefan
    Jones, Dan
    Abril, Caroline
    Pierce, Sherry
    Brandt, Mark
    Kantarjian, Hagop
    Ravandi, Farhad
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2011, 11 (04): : 361 - 366
  • [2] Combination of Sorafenib, Idarubicin, and Cytarabine Has a High Response Rate in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) Younger Than 65 Years
    Ravandi, Farhad
    Cortes, Jorge
    Faderl, Stefan
    Garcia-Manero, Guillermo
    O'Brien, Susan
    Borthakur, Gautam
    Pierce, Sherry
    Brandt, Mark
    Lang, Marites
    Zhang, Weiguo
    Luthra, Rajyalakshmi
    Jones, Dan
    Levis, Mark J.
    Konopleva, Marina
    Andreeff, Michael
    Kantarjian, Hagop M.
    BLOOD, 2008, 112 (11) : 285 - 285
  • [3] COMBINATION OF IDARUBICIN, HIGH DOSE CYTARABINE AND SORAFENIB IS HIGHLY EFFECTIVE IN ACHIEVING REMISSION IN NEWLY DIAGNOSED, FLT3-MUTATED ACUTE MYELOID LEUKEMIA
    Ravandi, F.
    Andreeff, M.
    Garcia-Manero, G.
    Faderl, S.
    Konopleva, M.
    O'Brien, S.
    Byrd, A.
    Brandt, M.
    Zhang, W.
    Jones, D.
    Levis, M.
    Cortes, J.
    Kantarjian, H.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 335 - 335
  • [4] Tipifarnib in combination with idarubicin and cytarabine in patients with newly diagnosed acute myeloid leukemia (AML) or high risk myelodysplastic syndrome (MDS).
    Ravandi-Kashani, F.
    Kantarjian, H.
    Garcia-Manero, G.
    O'Brien, S.
    Verstovsek, S.
    Estrov, Z.
    Faderl, S.
    Giles, F.
    Wright, J.
    Cortes, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 351S - 351S
  • [5] INDOXIMOD IN COMBINATION WITH IDARUBICIN AND CYTARABINE FOR UPFRONT TREATMENT OF PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA (AML): PHASE 1 REPORT
    Emadi, A.
    Holtzman, N. G.
    Imran, M.
    El Chaer, F.
    Koka, M.
    Singh, Z.
    Shahlaee, A.
    Sausville, E. A.
    Law, J.
    Lee, S. T.
    Banerjee, A.
    Rapoport, A.
    Baer, M. R.
    Duong, V. H.
    Munn, D. H.
    Loken, M.
    Kennedy, E.
    Vahanian, N.
    Link, C.
    HAEMATOLOGICA, 2017, 102 : 375 - 375
  • [6] MicroRNA Expression and Response to Sorafenib, Cytarabine, and Idarubicin in Patients with Acute Myeloid Leukemia
    Powers, M. P.
    Rushton, J. R.
    Yao, H.
    Barkoh, B. A.
    Jones, D.
    Luthra, R.
    MODERN PATHOLOGY, 2010, 23 : 427A - 427A
  • [7] MicroRNA Expression and Response to Sorafenib, Cytarabine, and Idarubicin in Patients with Acute Myeloid Leukemia
    Powers, M. P.
    Rushton, J. R.
    Yao, H.
    Barkoh, B. A.
    Jones, D.
    Luthra, R.
    LABORATORY INVESTIGATION, 2010, 90 : 427A - 427A
  • [8] Sequential Venetoclax and FLT3 Inhibitors in Combination With Hypomethylating Agents or Low-Dose Chemotherapy in Newly Diagnosed, Unfit, FLT3-Mutant Acute Myeloid Leukemia Patients
    Al Mahmasani, Layal
    Moukalled, Nour
    El Cheikh, Jean
    Bazarbachi, Ali
    Abou Dalle, Iman
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S228 - S228
  • [9] Mitoxantrone and etoposide in patients with newly diagnosed acute myeloid leukemia with persistent leukemia after a course of therapy with cytarabine and idarubicin
    McHayleh, Wassim
    Sehgal, Rajesh
    Redner, Robert L.
    Raptis, Anastasios
    Agha, Mounzer
    Natale, James
    Luong, The Minh
    Schlesselman, James J.
    Foon, Kennteh A.
    Boyiadzis, Michael
    LEUKEMIA & LYMPHOMA, 2009, 50 (11) : 1848 - 1853
  • [10] Clofarabine, Idarubicin, and Cytarabine (CIA) As Frontline Therapy for Patients <=60 Years with Newly Diagnosed Acute Myeloid Leukemia (AML)
    Nazha, Aziz
    Ravandi, Farhad
    Kantarjian, Hagop M.
    Huang, Xuelin
    Choi, Sangbum
    Garcia-Manero, Guillermo
    Jabbour, Elias J.
    Borthakur, Gautam
    Kadia, Tapan M.
    Konopleva, Marina
    Cortes, Jorge E.
    Ferrajoli, Alessandra
    Kornblau, Steven M.
    Andreeff, Michael
    Estrov, Zeev
    Daver, Naval G.
    Pemmaraju, Naveen
    Du, Mm
    Brandt, Mark
    Faderl, Stefan
    BLOOD, 2012, 120 (21)
12345